Johnson & Johnson (JNJ) and Protagonist Therapeutics (PTGX) said Friday their jointly developed drug icotrokinra largely met its primary endpoint of significant skin clearance in a phase 3 study of adults and adolescents with moderate or greater plaque psoriasis on high-impact skin areas.
The 16-week study showed 57% of patients treated with icotrokinra showed clear or almost clear skin compared with 6% for those receiving a placebo, the companies said.
The drug also showed a "favorable" safety profile comparable to the placebo, the companies said.
Protagonist said it expects to submit a new drug application for icotrokinra with the US Food and Drug Administration this year.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。